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Mesenchymal stromal/stem cells (MSCs) possess immunomodulatory and reparative properties. Through
specific interactionswith immune cells that participate in both innate and adaptive responses,MSCs exposed
to an inflammatory microenvironment can downregulate many immune effector functions. Clinical trials
focusing onMSCs to treat graft-versus-host disease (GvHD) andautoimmunediseasesare underway.Current
analyses suggest that MSCs will improve cell and solid organ transplantation by ameliorating rejection and
possibly eliminating the requirement for prolonged regimens of conventional immunosuppressive drugs.
This review examines the in vitro and in vivo evidence for the clinical use of bone marrow derived MSCs.Transplantation is a life-preserving therapy for many patients
with established organ failure. The development of immunosup-
pressive drugs has made cell and solid organ transplantation
a viable therapeutic option, as rejection of foreign tissues can
be delayed or prevented. However, long term administration of
nonspecific immunosuppression has detrimental consequences
including increased susceptibility to infection, a higher risk of
tumorigenesis, cardiovascular complications, de novo induction
of diabetes and renal failure (Lo´pez et al., 2006). Therefore, the
development of an alternative immunosuppressive therapy that
is both specific and non-toxic is essential with regard to
improving the long term outcome for transplant patients. A
growing body of evidence suggests that a multipotent popula-
tion of mesenchymal stromal cells (MSCs), also called mesen-
chymal stem cells, may fill this need due to their capacity to
modulate immune responses via a host of direct and indirect
interactions with a broad range of cell types. In this review, we
discuss the results of in vitro and in vivo experiments that
examine the mechanistic interactions of bone marrow stromal
cells (BMSCs) with components of the immune system. Early
stage clinical application of these cells is underway, despite
considerable variability in preclinical experimental findings, and
while initial results appear promising, there remain many open
questions as to how BMSCs may function in a setting of thera-
peutic transplantation.
An Introduction to MSCs
In the 1960s and 1970s, Friedenstein and colleagues described
the presence of stromal cells and bone forming cells within the
bonemarrow (Friedenstein et al., 1976). This work demonstrated
that a subpopulation of bone marrow cells displayed osteogenic
potential and were characterized by their rapid adherence to
tissue culture plastic, fibroblast-like appearance, and their
colony forming unit (CFU) capacity. Transplantation of bone
marrow cells beneath the kidney capsule or in the subcutaneous
space demonstrated the capacity of bone marrow cells to form
ectopic marrow, consisting of trabecular bone, adipocytes,
and myelosupportive stroma (Friedenstein et al., 1966, 1974;Owen, 1988). Subsequently, in the late 1980s, Owen and Caplan
elaborated on this early work and proposed the idea of a nonhe-
matopoietic adult stem cell in the bone marrow (Caplan, 1991;
Owen, 1988). The term mesenchymal stem cell was coined by
Caplan in 1991 (Caplan, 1991). Human bone marrow-derived
MSCs were first isolated by Caplan’s group (Haynesworth
et al., 1992b), and the same group identified the first MSC
expressed antigens that react with SH-2 (CD105) and SH-3
(CD73) (Haynesworth et al., 1992a). Since then, MSCs have
been isolated from a number of other sources, including
umbilical cord blood, adipose tissue, muscle, and liver (da Silva
Meirelles et al., 2006; Kern et al., 2006).
Initially, MSCswere thought tomediate tissue and organ repair
by virtue of a multilineage differentiation potential that enabled
them to replace damaged cells (Mahmood et al., 2003; Murphy
et al., 2003). However, subsequent findings suggest that this
mechanism is unlikely (Caplan and Dennis, 2006; Prockop,
2009). It is now widely believed that in response to tissue injury,
MSCs home to the site of damage and encourage repair through
the production of trophic factors, including growth factors, cyto-
kines, and antioxidants (Block et al., 2009; Chen et al., 2008;
Karp and Leng Teo, 2009), some of which provide the basis for
their capacity to modulate immune responses.
MSC Phenotype, Characteristics, and Culture
While a broad, promiscuous differentiation potential sometimes
ascribed to MSCs remains debated in the literature, a subset of
MSCs has been shown to contain amultipotent stem cell (Bianco
et al., 2008) with the ability to differentiate into adipose tissue,
bone, and cartilage (Pittenger et al., 1999). In the absence of
amarker specific for thesemultipotent MSCs, a panel of markers
has been outlined by the International Society for Cellular
Therapy (ISCT) and widely adopted by the field to phenotypically
define the population. The ISCT has stated that ‘‘MSCs must
express CD105, CD73 and CD90 and lack the expression of
CD45, CD34, CD14, or CD11b, CD79a or CD19 and HLA-DR
surface molecules’’ (Dominici et al., 2006). Furthermore, MSCs
are selected in vitro by adherence to tissue-culture-treated
plastic. Significant advances have been achieved over the lastCell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc. 431
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humanMSC populations in particular. However, it is important to
add that the above criteria serve as a means to characterize the
cells but that the combined surface phenotype is not definitive. It
is likely that this definition will continue to evolve over time.
It should also be noted that multiple differences between
mouse and human MSCs have been reported. Mouse MSCs
have not yet been formally characterized with respect to surface
antigen expression but generally follow the human MSC criteria.
While it is relatively easy to isolate and expand human MSCs,
mouse MSC cultures can be highly contaminated with hemato-
poietic cells, even after multiple passages, and this heteroge-
neity likely contributes to the conflicting results produced by
different laboratories, each utilizing different populations of
‘‘MSCs.’’
MSCs can be passaged in vitro through many rounds of
culture, yet there are indications that chromosomal modifica-
tions, replicative senescence, and loss of function can occur
as a result of prolonged ex vivo culture (Briquet et al., 2010;Miura
et al., 2006; Wagner et al., 2008), and therefore, the consensus is
that MSCs should be used for cell therapy only at low passages.
Variations in in vitro culture conditions can lead to differences in
MSC function. In particular, MSCs cultured under hypoxic condi-
tions (low oxygen) display enhanced tissue regeneration poten-
tial in mouse models of myocardial infarction, via elevated
production of trophic factors (Hu et al., 2008; Rosova´ et al.,
2008). While in the majority of studies MSCs are cultured under
normoxic conditions, it is important that individual reports
highlight the specific conditions used in order to understand
differences between laboratories and to determine the optimal
conditions for MSC culture to enable experimental data to be
relevant for clinical studies.
A better understanding of the in vivo origin of MSCs has been
eagerly awaited since the realization that MSCs held significant
reparative and immune modulatory potential. Progress toward
this goal has emerged over the past 2 years, with data suggest-
ing that MSCs arise from the perivascular zone and that they can
function as vascular pericytes (Crisan et al., 2008). However,
while MSCs share many similarities with pericytes, there are
subtle differences that distinguish these populations, and there-
fore, further data are required to substantiate this hypothesis.
Interestingly, it appears that fibroblasts share many of the
same characteristics as MSCs, including immunosuppressive
effects, differentiation potential, plastic adherence, and surface
marker expression in vitro (reviewed in Haniffa et al., 2009).
Some evidence exists to suggest that both MSC and fibroblasts
display trilineage differentiation potential at the clonal level (Chen
et al., 2007; Muraglia et al., 2000). Importantly, the frequency of
MSCs appears to be very low in vivo, making them rare in
comparison to fibroblasts. The high risk of ‘‘mistaken identity’’
between these populations highlights that the development of
assays that can distinguish MSCs from similar cells should be
a high priority for the field.
To date, there has been much ambiguity with regard to the
correct nomenclature used to describe this population of cells,
whichare referred toasmesenchymal stemcellsbysomeauthors
and mesenchymal stromal cells by others (Bianco et al., 2008).
Because bone marrow stromal cells (BMSCs) are the best char-
acterized population, we focus our review on these cells.432 Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc.BMSC Immune Modulation
The initial studies carried out by Friedenstein and colleagues in
the 1960s and 1970s and the subsequent work by Caplan and
Owen demonstrated the existence of a subpopulation of multi-
potent cells within the bone marrow that exhibited the capacity
to support hematopoiesis (Caplan, 1991; Friedenstein et al.,
1966; Friedenstein et al., 1970; Friedenstein et al., 1974; Owen,
1988). An array of studies attempted to harness the hematopoi-
esis support property of BMSCs to facilitate or enhance hemato-
poietic stem cell (HSC) engraftment. In 1995, autologous,
culture-expanded BMSCs were given to patients with hemato-
logical malignancies that were in complete remission and
demonstrated safety with no reports of adverse events (Lazarus
et al., 1995). Subsequently, a phase I/II trial in patients receiving
myeloablative therapy for breast cancer demonstrated the
capacity of autologous BMSCs to enhance HSC engraftment
(Koc¸ et al., 2002).
Bartholomew and colleagues were one of the first groups to
extend the study of how BMSCs impact the formation and
engraftment of blood cells to how they influence the function of
mature immune cells. They did so by demonstrating that BMSCs
are immunosuppressive in vitro and in vivo using a baboon skin
allograft model (Bartholomew et al., 2002). Di Nicola et al. (2002)
went a step further by identifying that soluble factors are impor-
tant in BMSC-mediated immune modulation. Furthermore,
a large body of in vitro data supported these early studies by
demonstrating an immunosuppressive role for BMSCs via
suppression of T cell proliferation (Aggarwal and Pittenger,
2005; Glennie et al., 2005; Klyushnenkova et al., 2005; Krampera
et al., 2003; Potian et al., 2003; Tse et al., 2003) or throughmodu-
lation of antigen-presenting cell phenotype and function (Beyth
et al., 2005; Groh et al., 2005; Jiang et al., 2005; Zhang et al.,
2009; Zhang et al., 2004). Armed with the knowledge that
BMSCs displayed immunosuppressive properties, two indepen-
dent groups used ex vivo expandedBMSCs to treat patients with
steroid refractory graft-versus-host disease (GvHD) in small
scale pilot studies (Lazarus et al., 2005; Le Blanc et al., 2004)
with promising results. Furthermore, BMSCs are currently in
trials for use in Crohn’s disease, type 1 diabetes mellitus, and
multiple sclerosis (www.clinicaltrials.gov) (Ankrum and Karp,
2010). While preliminary results look encouraging, there is
currently a distinct lack of mechanistic data with regard to how
BMSCs regulate immune cells in vivo. Experimental progress is
being made toward filling in these gaps in our understanding,
as discussed below.
Transplantation Rejection and the Impact of BMSCs
The paramount goal in transplantation is the acquisition of a state
of tolerance or immunological unresponsiveness, and evidence
is mounting to suggest that BMSCs may facilitate this outcome.
In addition to their ability to produce trophic factors, BMSCs also
exhibit potent anti-inflammatory effects both in vitro and in vivo.
In this fashion, BMSCs have the capacity to regulate the activity
of T cells, B cells, DCs, natural killer cells (NKs), and macro-
phages (Asari et al., 2009; Ne´meth et al., 2009; Sheng et al.,
2008; Spaggiari et al., 2008) either directly through cell:cell
contact or indirectly via the production of soluble factors. Along-
side these cellular interactions, the homing of BMSCs to
sites of inflammatory insult and subsequent activation of
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suggest that BMSCs have the potential to regulate the immune
response in a highly specific manner (Ding et al., 2010; Ren
et al., 2008).
Interactions between BMSCs and T Cells
Transplant rejection is typically mediated by both T cell-medi-
ated and humoral- or antibody-mediated immune responses
(Colvin and Smith, 2005; Hall et al., 1978). The induction of
T cell proliferation and activation of effector functions is the
key driving force in the majority of rejection cases (Hall et al.,
1978). Following solid organ transplantation, alloantigen can be
presented to naive and memory T cells via donor or host
antigen-presenting cells (APCs) (LaRosa et al., 2007; Shoskes
and Wood, 1994) expressing major histocompatibility (MHC)
molecules. In response to alloantigen stimulation, T cells are
activated, proliferate, and differentiate into effector cells. Dif-
ferent subsets of effector T cells are defined by their precise
properties, and induction of a specific effector subset is deter-
mined by the microenvironment in which the activation takes
place (Heidt et al., 2010; Murphy and Stockinger, 2010).
BMSC Modulation of T Cells
BMSCs have been shown repeatedly to suppress T cell prolifer-
ation in vitro, whether mitogen or alloantigen driven (Di Nicola
et al., 2002; Ding et al., 2009; English et al., 2007; Glennie
et al., 2005), but, notably, have little effect on virally driven
T cell proliferation (Karlsson et al., 2008). This suppression is
not thought to be MHC restricted (Comoli et al., 2008; Le Blanc
et al., 2008). The effect of BMSCs on T cell proliferation appears
to be dependent on the inflammatory environment present when
the two cell types interact (Najar et al., 2009; Polchert et al., 2008;
Ren et al., 2008). For example, BMSC mediated inhibition of
T cell proliferation occurs under proinflammatory, but not
anti-inflammatory, conditions (Comoli et al., 2008). These obser-
vations correlate with mechanistic studies that identified a
requirement for proinflammatory cytokines (IFN-g, TNF-a, and/
or IL-1b) to elicit BMSC activation (Ren et al., 2008). An in vivo
GvHD model further substantiated such views in that IFN-g
was demonstrated to be necessary for BMSCs to suppress
disease development (Polchert et al., 2008).
Coculture with BMSCs also modifies the ratio of CD4+ T cell
subsets. In particular, a skewing that favors an increase in
regulatory T cells (Tregs) and Th1 cells that accompanies a corre-
sponding decrease in Th2 and Th17 cells is typically observed
(Casiraghi et al., 2008; Ge et al., 2009; Kong et al., 2009; Rafei
et al., 2009). This augmentation of T cell subsets was demon-
strated in semi- and fully allogeneic mouse cardiac allograft
transplantation models, a mouse model of experimental autoim-
mune encaphelomyelitis, as well as a rat model of experimental
autoimmune myasthenia gravis (Casiraghi et al., 2008; Ge et al.,
2009; Kong et al., 2009; Rafei et al., 2009).
The increase in the frequency of Tregs after coculture with
BMSCs is significant in a transplantation setting, as Tregs
typically maintain tolerance to self-antigens and assist in the
prevention of autoimmunity. Tregs can also control alloreactive
T cell responses (Long and Wood, 2009; Nadig et al., 2010;
Wood and Sakaguchi, 2003). In vivo, BMSC-induced Tregs
were demonstrated to be donor specific (Casiraghi et al.,
2008). Mechanistically, the factors required for the BMSC driven
generation of Tregs (analyzed by an increase in expression of thetranscription factor FoxP3 and the cell surface marker CD25,
IL-2ra chain) include PGE2, TGF-b, and cell-cell contact, acting
within a nonredundant capacity (English et al., 2009).
BMSCs have been demonstrated to inhibit the proliferation of
the CD8+ T cell subpopulation. Some studies have also shown
suppression of CD8+ T cell-mediated cytotoxicity (Rasmusson
et al., 2007), but other reports conflict with these findings (Ram-
asamy et al., 2008). This discrepancy can perhaps be explained
by an actual effect of BMSCs on total T cell number, via an
impact on cell death. That is, if the number of CD8+ T cells is
decreased during coculture with BMSCs, the overall cytotoxic
effect of the remaining population will be reduced. Meanwhile,
the reciprocal relationship does not appear to exist, since
BMSCs do not appear to be targeted for destruction by effector
CD8+ T cells (Rasmusson et al., 2007).
Additionally, unconventional T cells, such as invariant natural
killer T (iNKT) cells and gdT cells, appear to be regulated by
BMSCs in a similar way to conventional T cells, in that coculture
results in the inhibition of proliferation (Prigione et al., 2009).
While BMSCs induced the activation of iNKTs, a decrease in
the production of IFN-g was observed. In this particular study
BMSCs were identified as a target of gd T cell cytotoxicity
(Prigione et al., 2009).
Mechanisms Involved in BMSC Modulation of T Cells
The induction of T cell chemotaxis (via CXCR3 upregulation) also
appears to be important for BMSC-mediated antiproliferative
effects (Ren et al., 2009). This finding suggests that soluble
factors with a limited diffusion distance (or cell-cell contact) are
required. Nitric oxide (NO) has been demonstrated to act in
this manner. In response to IFN-g and either IL-1a, IL-1b, or
TNF-a, BMSCs upregulate expression of inducible nitric oxide
synthase (iNOS), thus generating an increase in the production
of NO (Ren et al., 2008). This upregulation of iNOS could occur
in response to an increase in the transcription factor C/EBPb
and probably also requires STAT-1 activation (Xu et al., 2009).
One possible mechanism by which NO could act in this capacity
is through the inhibition of Stat5 phosphorylation. The chemical
suppression of NOS reverses both the inhibition of Stat5
phosphorylation and T cell proliferation (Sato et al., 2007). This
specific combination of proinflammatory cytokines also stimu-
lates the release of chemokines from BMSCs (Ren et al., 2008).
While the experimental evidence from the mouse IFN-g/NO
model is strong, human BMSCs do not suppress T cell prolifer-
ation via NO production. Alternatively, it would appear that IDO
may be a key factor for human BMSCs (Ren et al., 2009).
IFN-g stimulation upregulates IDO production in human BMSCs
(Ryan et al., 2007), thus suppressing T cell proliferation either by
depleting tryptophan (an essential amino acid) in the local micro-
environment or by causing an increase in kynureninemetabolites
(Ren et al., 2009). However, data from other labs fail to demon-
strate a role for IDO in human BMSC modulation of T cell
proliferation but instead identify a role for HLA-G5 and IL-10 in
a cell-contact-dependent manner (Selmani et al., 2008). Thus,
the precise mechanisms in play still require further elucidation.
In addition to the upregulation of CXCR3, BMSCs also influ-
ence T cell chemotaxis by inducing an increase in CD62L and
CCR7 on the T cell surface. This change results in T cell homing
to the secondary lymphoid organs where the T cells are subse-
quently trapped (Li et al., 2008a).Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc. 433
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metalloproteinases (MMPs) and membrane type (MT) MMPs.
BMSC have been shown to be capable of producing MMP-1,
-2, -3, and -9, as well as MT1-MMP and MT3-MMP (Ding
et al., 2009; Lu et al., 2010; Rafei et al., 2008). MMPs secreted
by BMSC are thought to cleave CCL2 to generate an antago-
nistic molecule. The truncated CCL2 inhibits Th17 activation
(in an experimental model of multiple sclerosis) via the indirect
inhibition of STAT3 phosphorylation or, alternatively, by recruit-
ing a STAT3 specific phosphatase (Rafei et al., 2009). Further
research is required on this subject as CCR2 is not restricted
to Th17 or even Th1 cells; therefore, the possible effects of
antagonistic CCL2 on other T cell subsets must be established.
In another study, the production of MMP-2 and -9 by BMSCs
was correlated with a decrease in CD25 expression on CD4+
T cells and the inhibition of alloantigen driven proliferation
(Ding et al., 2009). Suppression of T cell proliferation could be
due to the induction of a state of IL-2 unresponsiveness (due
to loss of the IL-2ra chain, CD25) in T cells.
The discrepancy of results observed between in vitro and
in vivo experiments suggest that BMSCs suppress T cell prolifer-
ation through a range of different mechanisms, the importance of
which perhaps depends on the surrounding microenvironment
and cellular milieu at the time of interaction.
Interactions between BMSCs and B Cells
A proportion of both acute and chronic rejection episodes have
been attributed to antibody-mediated events (Colvin and Smith,
2005). The documented effects of BMSCs on B cell proliferation,
differentiation, and immunoglobulin (Ig) production have been
varied and, at times, contradictory. BMSCs were shown to
suppress LPS-induced B cell proliferation (at a high BMSC: B
cell ratio of 1:2, but not at the lower ratio of 1:10) and differenti-
ation, as well as to inhibit IgM and IgG1 secretion (Asari et al.,
2009). An in vivo mouse heart transplant model also demon-
strated that BMSCs reduced intragraft IgG as well as circulatory
IgM (Ge et al., 2009). The inhibition of Ig synthesis in the in vitro
system was demonstrated to proceed via the production of
MMPs and CCL2. The authors outline a possible CCL2 (and
CCL7) cleavage by the MMPs, converting a typically agonistic
CCL2 into an ‘‘antagonistic’’ form. It was suggested that this
antagonistic CCL2 binds to CCR2 on the B cell, leading to the
downregulation of BLIMP-1, which then directly inhibits Ig
synthesis (Rafei et al., 2008). A level of specificity was also
observed when this system was explored in rOVA-immunized
mice. The decrease in B cell BLIMP-1 mRNA in response to
coculture with BMSCs has been shown elsewhere (Asari et al.,
2009), as has the ability of MMPs to generate truncated CC che-
mokines with anti-inflammatory properties (McQuibban et al.,
2002). Therefore, this model appears to be a highly plausible
explanation for BMSC-generated soluble factors that have the
ability to regulate B cell Ig production.
BMSC Influence on Dendritic Cells
Through the capture of antigen in the periphery, migration to the
draining lymph nodes, and subsequent antigen presentation,
dendritic cells (DCs) can efficiently and rapidly activate T and B
cells. Both donor and recipient DCs can trigger rejection
following transplantation. Donor DCs, following an encounter
of inflammatory signals, express a high level of MHC class II
molecules that can display intact alloantigen to recipient434 Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc.T cells, thus initiating the direct pathway of allorecognition. The
indirect pathway operates when recipient DCs present pro-
cessed alloantigen (LaRosa et al., 2007; Shoskes and Wood,
1994).
BMSCs have been shown to inhibit differentiation of precur-
sors into DCs, as well as to suppress maturation (a process
that involves the upregulation of costimulatory molecules and
MHC class II) (Nauta et al., 2006a). Furthermore, DCs that have
been cultured with BMSCs are unable to stimulate CD4+ T cell
proliferation and produce an augmented cytokine profile
(Uccelli et al., 2008). By mediating changes to antigen-present-
ing cells, BMSCs are clearly in a position to modulate a host of
immune responses; however, the precise molecular mechanism
responsible for their impact on DC function remains under inves-
tigation. For example, it has been shown repeatedly that expo-
sure to BMSCs promotes a ‘‘regulatory’’ or ‘‘tolerogenic’’ DC
phenotype (Li et al., 2008b; Wehner et al., 2009; Zhang et al.,
2009). These tolerogenic DCs are maintained in an immature-
like state, indicated by the downregulation of CD11c, CD80,
CD86, and CD40 and upregulation of CD11b (Zhang et al.,
2009). This change in DC phenotype was not reversed by the
addition of LPS, suggesting the formation of a relatively stable
phenotype. Tolerogenic DCs also produced a lower level of
proinflammatory cytokines and a higher level of anti-inflamma-
tory cytokines in comparison with classical mature DCs. Rapidly
proliferating T cells were suppressed in the presence of a tolero-
genic DC population (Zhang et al., 2009). The ratio of T cell
subsets within the overall population also appears to be altered
in the presence of this tolerogenic DC population; an increase
in the frequency of Tregs has been documented (Ge et al.,
2009; Li et al., 2008b).
DC migration from the periphery toward more central T cell
areas in the lymph nodes typically occurs following the cell
surface upregulation of CCR7 and the concurrent downregula-
tion of E-cadherin. BMSCs inhibited both CCR7 expression
(therefore, chemotaxis to CCL19) and also dampened the loss
of E-cadherin from activated DCs (English et al., 2008). Should
the same changes occur in vivo, their combined effects would
maintain DCs in the periphery of the lymph node and, therefore,
limit T cell activation.
PGE2 and the Notch signaling pathway have both been impli-
cated in BMSC-mediated regulation of DCs. DCs have been
shown to express the PGE2 receptors EP2 and EP4, the activa-
tion of which led to an inhibition of DC function (Harizi et al.,
2003). Upregulation of both the Notch ligand, Jagged-2, and
the Notch-2 receptor on the cell surface of tolerogenic DCs
has been reported following exposure to BMSCs (Spaggiari
et al., 2009; Zhang et al., 2009). The inhibition of DC Jagged-2
expression resulted in the reversal of BMSC effects on T cell
proliferation (Zhang et al., 2009). It is possible that lateral Notch
activation could be occurring in the tolerogenic DC population.
Interactions between BMSCs and Other Immune Cells
Natural killer (NK) cell involvement can have a significant impact
on the outcome of organ transplantation. NK cells identify alloge-
neic cells either via the absence of self-MHC molecules on the
cell surface or by the recognition of stimulatory receptors. In
addition to the release of IFN-g and TNF-a, a potent cytolytic
response can be elicited following NK cell activation (LaRosa
et al., 2007).
Figure 1. BMSCs Delay Graft Rejection
through Multiple Immunomodulatory
Mechanisms
BMSCs potentially aid graft acceptance via the
generation of Tregs and tolerogenic (Tol) DCs. Re-
cruited BMSCs are activated by proinflammatory
cytokines generated through graft-induced inflam-
mation. BMSCs inhibit T cell proliferation, inhibit
cytotoxicity, and reduce CD25 surface expression
via an array of factors including NO, IDO, HLA-G5,
IL-10, MMPs, and CCL2. The Notch signaling
pathway, PGE2, and TGF-b are thought to play
an important role in the regulation of DCs. BMSCs
also modulate B cells, NK cells, and macrophages
through similar mechanisms. Neutrophils are indi-
rectly modulated by BMSCs through macrophage
production of IL-10. Furthermore, BMSCs inhibit
the migration of DCs to the lymph nodes, thus
maintaining alloantigen-loaded APCs in the graft.
The enhancement of T cell migration to the se-
condary lymphoid organs, following the BMSC-
induced upregulation of CCR7 and CD62L, gener-
ates a system in which stimulating DCs and APCs
are effectively compartmentalised. The combina-
tion of the generation of regulatory mediators,
such as Tregs and tolerogenic DCs, in addition to
the prevention of T cell activation (in response to
alloantigen presentation) could serve to prevent
graft rejection. M4, macrophage; N4, neutrophil;
iDC, immature DC; mDC, mature DC.
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significantly reduced IFN-g production, and prevented the
upregulation of the activation markers NKp30 and NKG2D on
NK cells (Spaggiari et al., 2008). A potential synergistic activity
of IDO and PGE2 has been implicated for the BMSC-mediated
inhibition of (IL-2 induced) NK cell proliferation and cytolytic
activity (Spaggiari et al., 2008). The impact of BMSCs on other
immune cells of the innate response has been poorly character-
ized.
An abundant neutrophil infiltrate can be found in rejected
organs. BMSCs were demonstrated to have an indirect impact
on neutrophil migration via the modulation of macrophage
cytokine release. BMSCs stimulated the release of IL-10 from
tissue-resident macrophages, thus limiting the extent of the
neutrophil infiltrate (Ne´meth et al., 2009). In a mouse model of
sepsis, it was postulated that TLR4 stimulation combined with
increased NO and TNF-a exposure resulted in NF-kB activation
and, therefore, an upregulation of COX2 in BMSCs. This se-
quence of events would increase the availability of substrates
for PGE2 synthesis. PGE2 released by BMSCs can bind to EP2
and EP4 on the macrophage cell surface; a subsequent increase
in cAMP is potentially responsible for the increase in IL-10
(Ne´meth et al., 2009).
In summary, BMSCs modulate the immune response through
an array of mechanisms, which will likely aid graft acceptance in
the setting of cellular and solid organ transplantation (Figure 1).
ImmuneModulation byMSCDerived fromOther Tissues
It is also important to reiterate that MSCs have been isolated
from a number of tissues in addition to bone marrow, such as
adipose tissue, Wharton’s jelly, and umbilical cord blood (da
Silva Meirelles et al., 2006; Kern et al., 2006; Yoo et al., 2009).
While the field has focused on bone-marrow-derived MSCs,
evidence that MSCs derived from other tissues also exhibitimmunosuppressive properties is beginning to emerge. A small
number of comparison studies of both mouse and human
BMSCs from different sources suggest measurable differences
in the regulatory effects on immune cells (Bochev et al., 2008;
Hegyi et al., 2010; Ivanova-Todorova et al., 2009). For example,
adipose-derivedMSCs had amore potent effect on the inhibition
of Ig synthesis and a greater inhibition of DC precursor differen-
tiation (Bochev et al., 2008; Ivanova-Todorova et al., 2009).
These observations stress the importance of understanding
the mechanism of action of the particular MSC population in
question and highlight the need for more exhaustive comparison
studies.
BMSCs As a Therapeutic Tool in Cell and Solid Organ
Transplantation
Source of BMSCs
BMSCs to be used in combination with cell or organ transplants
may come from autologous, donor-derived (allogenic), or third
party (allogeneic, derived from neither recipient nor donor) sour-
ces. Autologous cells are clearly the safest option for clinical cell
therapy in terms of the relative risk of rejection or graft versus
host reactions. However, there are circumstances in which
healthy autologous, HLA-matched or haploidentical cells will
not be available. In these scenarios, an ‘‘off the shelf’’ therapy
consisting of third-party allogeneic BMSCs would provide an
immediate source ready for clinical utility, and is, therefore, theo-
retically very attractive. However, there are many important
considerations to be taken into account, given the mechanisms
by which BMSCs may exert their immunomodulatory functions,
as described above.
BMSC Number and Route of Administration
In addition to selecting the appropriate source when considering
clinical use of BMSCs, before this population is used inCell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc. 435
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numbers and route of administration must be determined. Intra-
venous administration has been utilized throughout human trials
and has also proven to be a suitable route for BMSC infusion in
animal models. An additional possibility is to infuse BMSCs into
the donor organ prior to transplantation. In a mouse model of
diabetes, BMSCs were introduced under the kidney capsule in
conjunction with the donor islets, facilitating graft acceptance
(Ding et al., 2009). This method could possibly aid the formation
of a transplant microenvironment in which BMSCs can exert
immunomodulatory effects. Further study is required to eluci-
date BMSC homing in a transplantation model.
In clinical trials to date, the number of BMSCs infused has
ranged from0.43 106 to 103 106/per kg of bodyweight (Le Blanc
et al., 2008; Macmillan et al., 2009). At this stage, no significant
correlation has beenmade between the dose of BMSCs received
and clinical outcome. Furthermore, single, double, and repeated
doses ofBMSCshavebeenadministered,with noobvious pattern
to the outcome observed in each variation of the protocol. For
example, some patients responded to a second infusion following
a nonresponse to the first, while others failed to respondevenafter
multiple infusions (Le Blanc et al., 2008).
Importantly, no BMSC-related adverse affects have been
recorded in clinical trials. In the aforementioned GvHD clinical
trial, patient mortality following BMSC infusion was mainly due
to opportunistic infection, which was not considered surprising
given the patient’s status (Le Blanc et al., 2008).
Recently details have emerged from larger-scale, placebo-
controlled phase III clinical trials utilizing third-party BMSC as a
first and second line therapy to treat GvHD and steroid-resistant
GvHD, respectively. A significant placebo effect was observed in
these studies, in that BMSCwere nomore effective than placebo
over all. In contrast, BMSC treatment did correlate with a signifi-
cant improvement in patients with steroid-resistant liver or
gastrointestinal GvHD (Mills, 2009). Again, these trials highlight
the importance of clarifying how BMSCs exert their effects
in vivo and achieving a better understanding of their interaction
(s) with existing drug therapies in order to facilitate successful
translation to the clinic.
Immunogenicity of Allogeneic BMSC
While BMSCs have been considered to be relatively immune
privileged, more recent findings suggest that non-self BMSCs
are immunogenic. In particular, under certain conditions, upre-
gulation of both MHC class I and class II on BMSCs has been
observed (Chan et al., 2008). A small number of reports provide
evidence that both human and mouse BMSCs have the capacity
to present antigen and, subsequently, induce effector T cell
responses in vitro (Franc¸ois et al., 2009; Romieu-Mourez et al.,
2009; Stagg et al., 2006) and memory T cell responses in vivo
(Nauta et al., 2006b). Nonetheless, preclinical models and clin-
ical trials using both syngeneic (or autologous) and allogeneic
BMSCs have demonstrated no adverse events associated with
allogeneic BMSCs (Chen et al., 2009; Le Blanc et al., 2008).
Moreover, data from a mouse model examining efficacy of
syngeneic and allogeneic BMSCs in wound repair indicate that
syngeneic and allogeneic BMSCs do not evoke an immune
response unlike allogeneic fibroblasts (Chen et al., 2009). Thus,
the degree to which allogeneic BMSCs may induce immune
responses in vivo remains unclear.436 Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc.Data from a clinical trials utilizing BMSC for treatment of acute,
steroid-resistant GvHD also indicates that the administration of
allogeneic BMSCs does not appear to trigger an immune
response. In this study, patients were given BMSCs from HLA-
identical, haploidentical, or third-party donors. Out of a total of
55 patients, 27 exhibited a ‘‘complete response’’ following one
dose of BMSCs; of this group, 2 patients received HLA-identical
BMSCs, 3 haploidentical, and 24 third party (Le Blanc et al.,
2008). This finding indicates that the administration of allogeneic
BMSCs does not significantly impact on the therapeutic
outcome, at least in the setting of GvHD. Indeed, one might
also speculate that BMSCs with an allogeneic origin might offer
amore beneficial clinical outcome and, if so, could perhaps shed
light into the mechanism by which the BMSCs impact the
immune response in a therapeutic setting. There are potentially
a number of significant advantages to be gained if third-party
BMSCs can be utilized. First, BMSCs can be generated in
bulk, providing a more economical option and potentially a
more uniform source of donor cells. In addition, the use of
third-party BMSCs enables cells to be available on demand so
that treatment does not have to be delayed during a period of
cell culture and characterization. This factor becomes even
more relevant in the case of organ availability for transplantation
from deceased donors.
Taking all of the available evidence into consideration, it
seems likely that the potential for BMSCs to act as APCs and,
therefore, become immunostimulatory is limited to a specific
combination of conditions. However, the clinical significance of
this possibility is clearly an important issue which warrants
further investigation in order to define the specific conditions
that could lead to a deleterious outcome.
Effects of Immunosuppressive Drugs on BMSC Function
As all transplant patients receive immunosuppressive drugs, it
would be important to fully understand the extent to which these
drugsmay impact on BMSC function. A number of in vivo studies
have explored the use of BMSCs in combination with conven-
tional immunosuppression. In a mouse allogeneic heart model,
BMSCs and rapamycin coordinated to yield a synergistic effect
and induced tolerance as measured by the absence of rejection
up to 100 days posttransplantation and subsequent acceptance
of donor-derived skin graft (Ge et al., 2009). The specificity of
tolerance was demonstrated by showing that a third-party skin
graft was not accepted by the treated recipients. However,
when amixed lymphocyte reaction was performed, the suppres-
sion of PBMC proliferation by rapamycin and tacrolimus was
adversely affected by the presence of human BMSCs. Yet, in
a separate system, BMSCs complemented the inhibition of
PBMC proliferation by mycophenolic acid (MPA) (Hoogduijn
et al., 2008). In both swine and rat models, the administration
of cyclosporine A (CsA) with BMSCs resulted in prolongation of
a composite tissue and skin graft, respectively (Kuo et al.,
2009; Sbano et al., 2008). This synergy between BMSCs and
MPA with regard to suppression of T cell proliferation could be
due to distinct mechanisms of action employed by BMSCs and
MPA. Therefore,MPAmight be the drug of choice in combination
therapy. It is likely that immunosuppressive drugs will be
required initially (following transplantation) to allow BMSC
survival and to create an environment in which BMSCs can
become activated in order to achieve their effect. Even if BMSCs
Table 1. Preclinical Models Utilizing MSC Immune Modulation and Repair Capacity
Disease model
Animal
Model MSC Source
Conventional
Immunosuppression Outcome References
Heart transplantation
(semi-allogeneic)
mouse donor bone marrow no long-term graft survival (Casiraghi et al., 2008)
Skin transplantation
(allogeneic)
rat donor bone marrow CsA,
certain groups
MSC + CSA, graft survival
prolongation; MSC alone,
accelerated rejection
(Sbano et al., 2008)
Islet transplantation
(allogeneic)
mouse syngeneic bone marrow no long-term graft survival (Ding et al., 2009)
Skin transplantation
(allogeneic)
baboon donor bone marrow no prolongation of donor
and third party skin grafts
(Bartholomew
et al., 2002)
GvHD mouse syngeneic bone marrow no prevention of disease (Ren et al., 2008)
Composite tissue
transplantation
(allogeneic)
swine donor bone marrow CsA,
certain groups
MSC alone, prolonged graft
survival; MSC + Irr + BMT + CsA,
significantly prolonged graft
survival
(Kuo et al., 2009)
GvHD mouse donor bone marrow no prevention of GvHD;
treatment of established GvHD
(Polchert et al., 2008)
Experimental autoimmune
encephalomyelitis
mouse allogeneic bone marrow no ameliorate disease (Rafei et al., 2009)
Sepsis mouse syngeneic bone marrow no ameliorate disease (Ne´meth et al., 2009)
Ischemic acute renal failure rat syngeneic bone marrow no improved renal function (To¨gel et al., 2005)
Osteoarthritis goat syngeneic bone marrow no regeneration of meniscal tissue (Murphy et al., 2003)
Critical-size bone defect dog allogeneic bone marrow no enhanced repair, no adverse
immune response
(Arinzeh et al., 2003)
Critical-size bone defect rabbit allogeneic peripheral
blood and bone marrow
no enhanced repair,
no adverse immune response
(Wan et al., 2006)
Heart transplantation
(allogeneic)
mouse recipient/donor/third party
bone marrow
rapamycin long term graft survival (Ge et al., 2009)
Myocardial infarction rat allogeneic bone marrow no improved global Lv function,
no evidence of inflammatory
response
(Dai et al., 2005)
Summary table detailing the outcomes of animal models utilizing MSC immune modulation and repair capacities. CsA, cyclosporine A; GvHD,
graft-versus-host disease; Irr, Irradiation, BMT, bone marrow transplant; Lv, left ventricular.
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their use could provide significant benefit in transplantation
models by reducing the overall load of immunosuppressive
drug therapy required to maintain long-term graft function.
In a number of animal models, BMSCs have been infused
without accompanying immunosuppression. For example, pan-
creatic islets transplanted to an immunocompromised mouse
were not rejected when introduced in combination with BMSCs,
as demonstrated by long-term normoglycaemia (Ding et al.,
2009).Monotherapyby infusionofBMSCsalonealsodelayedgraft
rejection in an immunocompetent semiallogeneic heart model
(Casiraghi et al., 2008). However, at least one report has shown
that BMSC administration alone has resulted in the acceleration
of graft rejection in an animal model (Sbano et al., 2008). Such
undesirable outcomes highlight the necessity for a better overall
understanding of the system in question to ensure that the use
of BMSCs and adjunctive therapy can be tailored effectively.
Nevertheless, data from animal studies (Table 1) and clinical
experience with MSCs (Table 2) suggest that modulation of the
immune response and the induction of tolerance can potentially
be achieved via the administration of MSCs (the lattermost real-istically following a brief period of immunosuppressive drug
administration), but a more conclusive interpretation remains
to be determined following long-term observation of treated
patients.
Trials that use MSC in solid organ transplantation (kidney) are
currently in their infancy (www.clinicaltrials.gov), and there are
over 100 clinical trials utilizing the immunomodulatory and
proreparative effects of MSC. The results of these trials will
undoubtedly provide further insight into the application of thera-
peutically administered MSC in transplantation.
Conclusion and Future Prospective
Overall, the ability of BMSCs to mediate inhibition of T cell prolif-
eration, DCmaturation andmigration, B cell Ig synthesis, and NK
function indicates that these cells have the capacity to subdue
the immune response. Furthermore, the generation of tolero-
genic DCs and Tregs represents a viable physiological mecha-
nism by which sufficient immunomodulation could occur in order
to offer clinical benefit.
One point that is clear is that BMSCs appear to require activa-
tion in order to develop their full immunomodulatory potential,Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc. 437
Table 2. Clinical Experience of MSC in Immune modulation
Disease Patients (N) MSC source
Conventional
Immunosuppression Outcome References
Acute GvHD (GI tract
and liver)
55 HLA-identical, haploidentical,
or mismatched bone marrow
yes 30 complete response (Le Blanc et al., 2008)
Acute GvHD 32 allogeneic bone marrow yes 77% of patients responded (Kebriaei et al., 2009)
Acute GvHD 192 allogeneic bone marrow
(prochymal)
yes no significant difference
from placebo overall
(Mills, 2009)
Acute GvHD
steroid-resistant
260 allogeneic bone marrow
(prochymal)
yes significant improvements
in patients with gastrointestinal
and liver GvHD
(Mills, 2009)
Multiple sclerosis 10 allogeneic bone marrow - variable responses (Mohyeddin Bonab
et al., 2007)
Scleroderma 1 allogeneic bone marrow - improved (Christopeit et al., 2008)
Summary table detailing the patient number, MSC source, use of immunosuppression, and outcome of clinical trials with MSCs. GI, gastrointestinal.
Cell Stem Cell
Reviewwhere signals produced by various immune cells act on the
BMSCs to effect a change and induce subsequent release of
mediators. These mediators then regulate the initiating or
surrounding cells, ‘‘closing the loop,’’ so to speak, on the cycle
of BMSC-mediated immune modulation. It may well be due to
this cycle of indirect events that so many conflicting findings
are present in the experimental literature. Indeed, a discrepancy
is often reported for in vitro assays with regard to whether
BMSCs regulate the activity of other cell populations via cell-
cell contact or soluble factors. One explanation is that soluble
factors drive chemotaxis of the immune cell to within close prox-
imity of the BMSCs. Cell-cell contact or diffuse mediators within
the microenvironment can subsequently enhance suppression
or immunomodulation. It is highly plausible that such a require-
ment for recruitment exists in vivo, yet these scenarios are
understandably difficult to replicate outside of a live recipient.
Key mechanistic differences have been observed between
human and mouse BMSCs, which underscores that caution
should be exercised when attempting to translate results from
mouse in vivo models to understand clinical events. Nonethe-
less, mouse models remain an extremely useful experimental
tool. A number of contradictory findings resulting from both
in vitro and in vivo animal models can perhaps be explained
by the heterogeneity of cellular populations deemed to be
‘‘BMSCs.’’ Indisputably, the field would benefit from clear and
defined descriptions of populations used in each study, as well
as the ability to prospectively isolate relatively pure MSC
populations.
Theoretically, BMSCs have the potential to enhance cancer
progression as they have the ability to generate an environment
in which the immune response is suppressed (and, therefore,
also the immune response to the tumor). Although BMSCs prolif-
erate vigorously in vitro, little evidence of significant in vivo cell
division has been reported. The engraftment of infused BMSCs
also appears to be limited. On the other hand, BMSCs secrete
a plethora of growth factors, cytokines, and MMPs, including
VEGF and IL-6, that could potentially drive tumor growth.
VEGF is known to drive angiogenesis, a requirement for tumor
growth and subsequent metastasis (Ko¨gler et al., 2005). Further
evidence demonstrates that BMSCs are recruited to sites of
neoplasia, where they integrate into the tumor-associated438 Cell Stem Cell 7, October 8, 2010 ª2010 Elsevier Inc.stroma (Spaeth et al., 2009). Consequently, further investigation
with regard to the potential adverse effects of BMSC infusion
must be undertaken.
As discussed above, in vivo models have shown that BMSCs
can be used in combination with a number of immunosuppres-
sive drugs currently utilized in the clinic. The implementation
of a short-term regimen of conventional immunosuppression
alongside BMSC infusion looks promising and has the potential
to induce tolerance in the recipient (Ge et al., 2009). The safety
and efficacy of BMSC administration looks encouraging, yet
long-term patient observation must be undertaken to ensure
that no significant adverse affects are caused by infusion of
in vitro cultured BMSCs (Le Blanc et al., 2008).
Data that emerges from early clinical trials that use BMSCs in
cellular or solid organ transplantation settings will undoubtedly
offer important insights for the field. However, optimization of
the regimen implemented, cell number, and route of administra-
tion must be undertaken if the full potential of BMSCs is to be
realized. The complexity of the potential interactions between
MSCs and the variety of immune cell mediators clearly points
to the importance of additional in vivo studies, in a range of
experimental models, in order to establish the role of BMSCs
as well as to further elucidate the immunoregulatory mecha-
nisms at play in different clinical situations.ACKNOWLEDGMENTS
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